Literature DB >> 15049780

Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels.

L J M Carvalho1, S G Oliveira, M Theisen, F A Alves, M C R Andrade, G M Zanini, M C O Brígido, C Oeuvray, M M Póvoa, J A P C Muniz, P Druilhe, C T Daniel-Ribeiro.   

Abstract

The immunogenicity and protective efficacy of various antigen-adjuvant formulations derived either from the merozoite-surface protein-3 (MSP-3) or the glutamate-rich protein (GLURP) of Plasmodium falciparum were evaluated in Saimiri sciureus monkeys. These proteins were selected for immunogenicity studies based primarily on their capacity of inducing an antibody-dependent cellular inhibition effect on parasite growth. Some of the S. sciureus monkeys immunized with MSP-3(212-380)-AS02 or GLURP(27-500)-alum were able to fully or partially control parasitaemia upon an experimental P. falciparum [Falciparum Uganda Palo Alto (FUP-SP) strain] blood-stage infection, and this protection was related to the prechallenge antibody titres induced. The data are indicative that MSP-3 and GLURP can induce protective immunity against an experimental P. falciparum infection using adjuvants that are acceptable for human use and this should trigger further studies with those new antigens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15049780     DOI: 10.1111/j.0300-9475.2004.01409.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  20 in total

1.  Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.

Authors:  Régine Audran; Michel Cachat; Floriana Lurati; Soe Soe; Odile Leroy; Giampietro Corradin; Pierre Druilhe; François Spertini
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

2.  Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response.

Authors:  Suman Mazumdar; Paushali Mukherjee; Syed Shams Yazdani; S K Jain; Asif Mohmmed; Virander Singh Chauhan
Journal:  Infect Immun       Date:  2009-11-23       Impact factor: 3.441

Review 3.  Platform for Plasmodium vivax vaccine discovery and development.

Authors:  Sócrates Herrera Valencia; Diana Carolina Rodríguez; Diana Lucía Acero; Vanessa Ocampo; Myriam Arévalo-Herrera
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

4.  Identifying Plasmodium falciparum merozoite surface antigen 3 (MSP3) protein peptides that bind specifically to erythrocytes and inhibit merozoite invasion.

Authors:  Luis E Rodríguez; Hernando Curtidor; Marisol Ocampo; Javier Garcia; Alvaro Puentes; John Valbuena; Ricardo Vera; Ramses López; Manuel E Patarroyo
Journal:  Protein Sci       Date:  2005-07       Impact factor: 6.725

5.  Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants.

Authors:  Leonardo J M Carvalho; Francisco A Alves; Cesare Bianco; Salma G Oliveira; Graziela M Zanini; Soe Soe; Pierre Druilhe; Michael Theisen; José A P C Muniz; Cláudio T Daniel-Ribeiro
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

6.  A genetic approach to the de novo identification of targets of strain-specific immunity in malaria parasites.

Authors:  Axel Martinelli; Sandra Cheesman; Paul Hunt; Richard Culleton; Ahmed Raza; Margaret Mackinnon; Richard Carter
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-07       Impact factor: 11.205

7.  Characterization of a protective Escherichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure.

Authors:  Chiawei W Tsai; Peter F Duggan; Albert J Jin; Nicholas J Macdonald; Svetlana Kotova; Jacob Lebowitz; Darrell E Hurt; Richard L Shimp; Lynn Lambert; Louis H Miller; Carole A Long; Allan Saul; David L Narum
Journal:  Mol Biochem Parasitol       Date:  2008-11-27       Impact factor: 1.759

8.  Acquisition of antibodies to merozoite surface protein 3 among residents of Korogwe, north eastern Tanzania.

Authors:  Method D Segeja; Bruno P Mmbando; Misago D Seth; John P Lusingu; Martha M Lemnge
Journal:  BMC Infect Dis       Date:  2010-03-08       Impact factor: 3.090

9.  Associations between antibodies to a panel of Plasmodium falciparum specific antigens and response to sub-optimal antimalarial therapy in Kampala, Uganda.

Authors:  Chris E Keh; Aashish R Jha; Bridget Nzarubara; David E Lanar; Sheetij Dutta; Michael Theisen; Philip J Rosenthal; Grant Dorsey; Douglas F Nixon; Bryan Greenhouse
Journal:  PLoS One       Date:  2012-12-19       Impact factor: 3.240

10.  Association of IL-4 and IL-10 maternal haplotypes with immune responses to P. falciparum in mothers and newborns.

Authors:  Adjimon Gatien Lokossou; Célia Dechavanne; Aziz Bouraïma; David Courtin; Agnès Le Port; Rodolphe Ladékpo; Julien Noukpo; Désiré Bonou; Claude Ahouangninou; Audrey Sabbagh; Benjamin Fayomi; Achille Massougbodji; André Garcia; Florence Migot-Nabias
Journal:  BMC Infect Dis       Date:  2013-05-13       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.